Cargando…

Combined Heart and Kidney Transplantation: Clinical Experience in 100 Consecutive Patients

BACKGROUND: Combined heart and kidney transplantation (HKTx) is performed in patients with severe heart failure and advanced renal insufficiency. We analyzed the long‐term survival after HKTx, the influence of age and dialysis status, the rates of cardiac rejection, and the influence of sensitizatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Awad, Morcos Atef, Czer, Lawrence S. C., Emerson, Dominic, Jordan, Stanley, De Robertis, Michele A., Mirocha, James, Kransdorf, Evan, Chang, David H., Patel, Jignesh, Kittleson, Michelle, Ramzy, Danny, Chung, Joshua S., Cohen, J. Louis, Esmailian, Fardad, Trento, Alfredo, Kobashigawa, Jon A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405671/
https://www.ncbi.nlm.nih.gov/pubmed/30741603
http://dx.doi.org/10.1161/JAHA.118.010570
_version_ 1783401130782359552
author Awad, Morcos Atef
Czer, Lawrence S. C.
Emerson, Dominic
Jordan, Stanley
De Robertis, Michele A.
Mirocha, James
Kransdorf, Evan
Chang, David H.
Patel, Jignesh
Kittleson, Michelle
Ramzy, Danny
Chung, Joshua S.
Cohen, J. Louis
Esmailian, Fardad
Trento, Alfredo
Kobashigawa, Jon A.
author_facet Awad, Morcos Atef
Czer, Lawrence S. C.
Emerson, Dominic
Jordan, Stanley
De Robertis, Michele A.
Mirocha, James
Kransdorf, Evan
Chang, David H.
Patel, Jignesh
Kittleson, Michelle
Ramzy, Danny
Chung, Joshua S.
Cohen, J. Louis
Esmailian, Fardad
Trento, Alfredo
Kobashigawa, Jon A.
author_sort Awad, Morcos Atef
collection PubMed
description BACKGROUND: Combined heart and kidney transplantation (HKTx) is performed in patients with severe heart failure and advanced renal insufficiency. We analyzed the long‐term survival after HKTx, the influence of age and dialysis status, the rates of cardiac rejection, and the influence of sensitization. METHODS AND RESULTS: From June 1992 to December 2016, we performed 100 HKTx procedures. We compared older (≥60 years, n=53) with younger (<60 years, n=47) recipients, and recipients on preoperative dialysis (n=49) and not on dialysis (n=51). We analyzed actuarial freedom from any cardiac rejection, acute cellular rejection, and antibody‐mediated rejection, and survival rates by sensitized status with panel‐reactive antibody levels <10%, 10% to 50%, and >50%, and compared these survival rates with those from the United Network for Organ Sharing database. There was no difference in 15‐year survival between the 2 age groups (35±12.4% and 49±17.3%, ≥60 versus <60 years; P=0.45). There was no difference in 15‐year survival between the dialysis and nondialysis groups (44±13.4% and 37±15.2%, P=0.95). Actuarial freedom from any cardiac rejection (acute cellular rejection>0 or antibody‐mediated rejection>0) was 92±2.8% and 84±3.8%, acute cellular rejection (≥2R/3A) 98±1.5% and 94±2.5%, and antibody‐mediated rejection (≥1) 96±2.1% and 93±2.6% at 30 days and 1 year after HKTx. There was no difference in the 5‐year survival among recipients by sensitization status with panel‐reactive antibody levels <10%, 10% to 50%, and >50% (82±5.9%, 83±10.8%, and 92±8.0%; P=0.55). There was no difference in 15‐year survival after HKTx between the United Network for Organ Sharing database and our center (38±3.2% and 40±10.1%, respectively; P=0.45). CONCLUSIONS: HKTx is safe to perform in patients 60 years and older or younger than 60 years and with or without dialysis dependence, with excellent outcomes. The degree of panel‐reactive antibody sensitization did not appear to affect survival after HKTx.
format Online
Article
Text
id pubmed-6405671
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-64056712019-03-19 Combined Heart and Kidney Transplantation: Clinical Experience in 100 Consecutive Patients Awad, Morcos Atef Czer, Lawrence S. C. Emerson, Dominic Jordan, Stanley De Robertis, Michele A. Mirocha, James Kransdorf, Evan Chang, David H. Patel, Jignesh Kittleson, Michelle Ramzy, Danny Chung, Joshua S. Cohen, J. Louis Esmailian, Fardad Trento, Alfredo Kobashigawa, Jon A. J Am Heart Assoc Original Research BACKGROUND: Combined heart and kidney transplantation (HKTx) is performed in patients with severe heart failure and advanced renal insufficiency. We analyzed the long‐term survival after HKTx, the influence of age and dialysis status, the rates of cardiac rejection, and the influence of sensitization. METHODS AND RESULTS: From June 1992 to December 2016, we performed 100 HKTx procedures. We compared older (≥60 years, n=53) with younger (<60 years, n=47) recipients, and recipients on preoperative dialysis (n=49) and not on dialysis (n=51). We analyzed actuarial freedom from any cardiac rejection, acute cellular rejection, and antibody‐mediated rejection, and survival rates by sensitized status with panel‐reactive antibody levels <10%, 10% to 50%, and >50%, and compared these survival rates with those from the United Network for Organ Sharing database. There was no difference in 15‐year survival between the 2 age groups (35±12.4% and 49±17.3%, ≥60 versus <60 years; P=0.45). There was no difference in 15‐year survival between the dialysis and nondialysis groups (44±13.4% and 37±15.2%, P=0.95). Actuarial freedom from any cardiac rejection (acute cellular rejection>0 or antibody‐mediated rejection>0) was 92±2.8% and 84±3.8%, acute cellular rejection (≥2R/3A) 98±1.5% and 94±2.5%, and antibody‐mediated rejection (≥1) 96±2.1% and 93±2.6% at 30 days and 1 year after HKTx. There was no difference in the 5‐year survival among recipients by sensitization status with panel‐reactive antibody levels <10%, 10% to 50%, and >50% (82±5.9%, 83±10.8%, and 92±8.0%; P=0.55). There was no difference in 15‐year survival after HKTx between the United Network for Organ Sharing database and our center (38±3.2% and 40±10.1%, respectively; P=0.45). CONCLUSIONS: HKTx is safe to perform in patients 60 years and older or younger than 60 years and with or without dialysis dependence, with excellent outcomes. The degree of panel‐reactive antibody sensitization did not appear to affect survival after HKTx. John Wiley and Sons Inc. 2019-02-12 /pmc/articles/PMC6405671/ /pubmed/30741603 http://dx.doi.org/10.1161/JAHA.118.010570 Text en © 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Awad, Morcos Atef
Czer, Lawrence S. C.
Emerson, Dominic
Jordan, Stanley
De Robertis, Michele A.
Mirocha, James
Kransdorf, Evan
Chang, David H.
Patel, Jignesh
Kittleson, Michelle
Ramzy, Danny
Chung, Joshua S.
Cohen, J. Louis
Esmailian, Fardad
Trento, Alfredo
Kobashigawa, Jon A.
Combined Heart and Kidney Transplantation: Clinical Experience in 100 Consecutive Patients
title Combined Heart and Kidney Transplantation: Clinical Experience in 100 Consecutive Patients
title_full Combined Heart and Kidney Transplantation: Clinical Experience in 100 Consecutive Patients
title_fullStr Combined Heart and Kidney Transplantation: Clinical Experience in 100 Consecutive Patients
title_full_unstemmed Combined Heart and Kidney Transplantation: Clinical Experience in 100 Consecutive Patients
title_short Combined Heart and Kidney Transplantation: Clinical Experience in 100 Consecutive Patients
title_sort combined heart and kidney transplantation: clinical experience in 100 consecutive patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405671/
https://www.ncbi.nlm.nih.gov/pubmed/30741603
http://dx.doi.org/10.1161/JAHA.118.010570
work_keys_str_mv AT awadmorcosatef combinedheartandkidneytransplantationclinicalexperiencein100consecutivepatients
AT czerlawrencesc combinedheartandkidneytransplantationclinicalexperiencein100consecutivepatients
AT emersondominic combinedheartandkidneytransplantationclinicalexperiencein100consecutivepatients
AT jordanstanley combinedheartandkidneytransplantationclinicalexperiencein100consecutivepatients
AT derobertismichelea combinedheartandkidneytransplantationclinicalexperiencein100consecutivepatients
AT mirochajames combinedheartandkidneytransplantationclinicalexperiencein100consecutivepatients
AT kransdorfevan combinedheartandkidneytransplantationclinicalexperiencein100consecutivepatients
AT changdavidh combinedheartandkidneytransplantationclinicalexperiencein100consecutivepatients
AT pateljignesh combinedheartandkidneytransplantationclinicalexperiencein100consecutivepatients
AT kittlesonmichelle combinedheartandkidneytransplantationclinicalexperiencein100consecutivepatients
AT ramzydanny combinedheartandkidneytransplantationclinicalexperiencein100consecutivepatients
AT chungjoshuas combinedheartandkidneytransplantationclinicalexperiencein100consecutivepatients
AT cohenjlouis combinedheartandkidneytransplantationclinicalexperiencein100consecutivepatients
AT esmailianfardad combinedheartandkidneytransplantationclinicalexperiencein100consecutivepatients
AT trentoalfredo combinedheartandkidneytransplantationclinicalexperiencein100consecutivepatients
AT kobashigawajona combinedheartandkidneytransplantationclinicalexperiencein100consecutivepatients